In addition to its lead compound series, IB1000, IntraBio has developed a robust pipeline of compounds.
IB2000s: The IB2000 series have been used in compassionate-use clinical studies for Ménière’s disease, showing efficacy.
IB3000s: The IB3000 series (NAADP analogues and agonists) continue to demonstrate in pre-clinical studies enormous potential to elucidate new molecular pathways, thereby creating opportunities to treat a wide range of disease from Type 2 Diabetes to autism.
IB4000: IB4000 has been used in compassionate-use clinical studies for the treatment of NPC liver dysfunction, showing efficacy. IB4000 has been granted Orphan Drug Designation in both the US and EU for the treatment of NPC.IB1000 Series